PI Industries Q1 Review – Broadening Its Horizon With Active Pharma Ingredient Acquisition: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

PI Industries Ltd.’s operating performance during the quarter was impacted by one-time expenses pertaining to-

  1. Covid-19 management,

  2. consulting fees, and

  3. other costs related to various strategic projects.

Thus, despite this, the company reported Ebitda growth of 9% on the high base of last year.

PI Industries acquired the active pharma ingredient business division of lnd- Swift Laboratories Ltd. for Rs 15.3 billion, thereby marking its foray into the pharma segment.

The API business of Ind-Swift Labs has a diversified portfolio of 20 plus products, with a leadership position (global top five) in several of them, and a good research and development product pipeline.

Click on the attachment to read the full report:

Motilal Oswal PI Industries Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button